| Identification | Back Directory | [Name]
Spiro[benzofuran-2(3H),4'-piperidin]-3-amine, 1'-[3-(3,4-dihydro-1,5-naphthyridin-1(2H)-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl]-, (3R)- | [CAS]
2377352-49-1 | [Synonyms]
GDC-1971
SHP-1971
Spiro[benzofuran-2(3H),4'-piperidin]-3-amine, 1'-[3-(3,4-dihydro-1,5-naphthyridin-1(2H)-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl]-, (3R)- | [Molecular Formula]
C25H26N8O | [MOL File]
2377352-49-1.mol | [Molecular Weight]
454.54 |
| Chemical Properties | Back Directory | [Boiling point ]
714.1±60.0 °C(Predicted) | [density ]
1.48±0.1 g/cm3(Predicted) | [solubility ]
Acetonitrile: Slightly soluble: 0.1-1 mg/ml
Methanol: Sparingly soluble: 1-10 mg/ml | [form ]
Solid | [pka]
9.52±0.50(Predicted) | [color ]
Light yellow to yellow | [InChIKey]
RGCGBFIARQENML-ZEGQKUPANA-N | [SMILES]
N[C@@H]1C2=CC=CC=C2OC21CCN(C1=CN=C3C(N4CCCC5=NC=CC=C45)=NNC3=N1)CC2 |&1:1,r| |
| Hazard Information | Back Directory | [Description]
Migoprotafib is a protein tyrosine phosphate, also known as HPTP, inhibitor with potential as an antineoplastic agent. | [Uses]
Migoprotafib (GDC-1971) (compound 199) is a SHP2 inhibitor. Migoprotafib inhibits the MAPK/ERK signaling pathway, and exhibits antitumor activity[1][2]. | [in vivo]
Migoprotafib (60 mg/kg, po for 28 days) exhibits antitumor efficacy in RIT1 xenograft mouse models[2]. | Animal Model: | RIT1 xenograft mouse models[2] | | Dosage: | 60 mg/kg | | Administration: | po for 28 days | | Result: | Inhibited tumor growth. |
| [References]
[1] Alexander M, et al. Shp2 phosphatase inhibitors and methods of use thereof. Patent WO2019183367A1.
[2] Maddalo D, et al. RIT1M90I is a driver of lung adenocarcinoma tumorigenesis and resistance to targeted therapy[J]. 2024. |
|
|